NEW YORK, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston is investigating potential claims on behalf of investors in the securities of Sientra, Inc. (“Sientra” or the “Company”) (NASDAQ:SIEN). The investigation seeks to determine whether Sientra and certain of its officers and/or directors violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and whether a suit on behalf of investors should be filed as a result.
On September 24, 2015, the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (“MHRA”) suspended sales of Sientra’s Silimed-brand silicone breast implants following the discovery of contamination in the company’s Rio De Janeiro manufacturing plant. Following this news, the Company’s stock fell $9.02, or 43.83%, on September 24, 2015.
If you are an investor in Sientra, Inc. securities and wish to discuss your rights or if you are aware of any facts relating to this investigation, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at tjmckenna@gme-law.com or gegleston@gme-law.com.